Chao Gong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chao Gong has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Li Yang
Renal Division, Peking University First Hospital, Beijing, China
2 shared publications - Jiawei Zhang
Department of Health Policy and Management, School of Public Health, Peking University, Beijing 100191, China
1 shared publication - Quan Wang
Department of Health Policy and Management, School of Public Health, Peking University, Beijing, China
1 shared publication Runzhi Han
School of Public Health, Peking University, Beijing, China; Beijing Institute for Health Development, Peking University, Beijing, China; Key Laboratory of Health System Reform and Governance, National Health Commission of China(Peking University), Beijing, China
1 shared publication- Siqi Liu
Chinese Acad Med Sci & Peking Union Med Coll, Inst Med Informat & Lib, Ctr Hlth Syst & Policy, Beijing, Peoples R China
1 shared publication - Yang Liu
Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK
1 shared publication
Latest Publications
- Open Access
- 24 November 2024
- Published by BMJ in BMJ Surgery, Interventions, & Health Technologies
- Vol. 6 (1) , e000300
Financial incentives and motivational intervention to improve gastric cancer screening in China: a randomized controlled trial study protocol
Gastric cancer (GC) remains a significant global health challenge, with high mortality rates, particularly in low- and middle-income countries, like China. Early detection through screening is crucial for improving prognosis and reducing mortality. However, uptake of GC screening remains suboptimal, highlighting the need for effective interventions to promote screening participation. This study employs an experimental design to evaluate the effectiveness of two interventions, financial incentives and motivational interventions, in promoting GC screening uptake at the individual level. A large sample size will be recruited from high GC-burden provinces in China, and participants will be randomly assigned to intervention and control groups. Statistical analyses, including the χ² test and interrupted time series analysis, will be used to assess the impact of interventions on screening uptake and adherence. The research protocol was reviewed by the ethical review committee of the Peking University Health Science Center (2024097) and registered at the ClinicalTrials.gov. Findings from this study will be disseminated through peer-reviewed publications, conference presentations, and engagement with stakeholders to inform evidence-based strategies for improving GC screening and reducing GC-related morbidity and mortality.
- 24 November 2024
- Published by BMJ in BMJ Surgery, Interventions, & Health Technologies
- Vol. 6 (1) , e000300
Open AccessFinancial incentives and motivational intervention to improve gastric cancer screening in China: a randomized controlled trial study protocol
Gastric cancer (GC) remains a significant global health challenge, with high mortality rates, particularly in low- and middle-income countries, like China. Early detection through screening is crucial for improving prognosis and reducing mortality. However, uptake of GC screening remains suboptimal, highlighting the need for effective interventions to promote screening participation. This study employs an experimental design to evaluate the effectiveness of two interventions, financial incentives and motivational interventions, in promoting GC screening uptake at the individual level. A large sample size will be recruited from high GC-burden provinces in China, and participants will be randomly assigned to intervention and control groups. Statistical analyses, including the χ² test and interrupted time series analysis, will be used to assess the impact of interventions on screening uptake and adherence. The research protocol was reviewed by the ethical review committee of the Peking University Health Science Center (2024097) and registered at the ClinicalTrials.gov. Findings from this study will be disseminated through peer-reviewed publications, conference presentations, and engagement with stakeholders to inform evidence-based strategies for improving GC screening and reducing GC-related morbidity and mortality.